$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Xantoda for ALK-positive metastatic non-small cell lung cancer intolerant to crizotinib_ Kanghule
2025-10-19 11:44:20
Check Details
Gefitinib can treat locally advanced or metastatic non-small cell lung cancer that has previously received chemotherapy_ Kanghule
2025-10-19 11:44:20
Check Details
How should patients with lung cancer take dacomitinib correctly?
2025-10-19 11:44:20
Check Details
Has paclitaxel for injection been approved for marketing in China?
2025-10-19 11:44:20
Check Details
Ceritinib (Zanda) is a second-generation anti-cancer drug for ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Can medical insurance reimburse paclitaxel for injection?
2025-10-19 11:44:20
Check Details
Ceritinib (Zanda) has significant effect in first-line treatment of crizotinib-resistant lung cancer patients
2025-10-19 11:44:20
Check Details
Injectable paclitaxel combined with carboplatin as first-line treatment for non-small cell lung cancer_ Kanghule
2025-10-19 11:44:20
Check Details
Which lung cancer patients are suitable for treatment with dacomitinib?
2025-10-19 11:44:20
Check Details
How much will a box of Zanda cost after being included in medical insurance in 2021?
2025-10-19 11:44:20
Check Details
How much does paclitaxel for injection cost? Where can I buy it?
2025-10-19 11:44:20
Check Details
How long does it take for paclitaxel injection to take effect?
2025-10-19 11:44:20
Check Details
1
2
...
3878
3879
3880
3881
3882
3883
3884
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
2
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
3
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
4
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
5
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
6
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
7
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
8
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
9
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
10
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
11
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
12
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice